Pneumonia

HIV-1 Infected Ugandans Respond Poorly to Pneumonia Vaccine

Published in Vaccine Weekly, November 2nd, 1998

HIV-1 infected adults in Uganda are susceptible to streptococcal pneumonia, but respond poorly to the vaccine.

N. French and colleagues at the University of Minnesota assessed the feasibility of establishing a pneumococcal vaccine trial among HIV-1-infected adults in a community clinic in Entebbe, Uganda, and to characterize their responses to 23-valent pneumococcal polysaccharide vaccine ("Pneumococcal Vaccination in HIV-1-Infected Adults in Uganda: Humoral Response and Two Vaccine Failures," AIDS, September 10, 1998;12(13):1683-1689).

An open-label pilot trial was used to evaluate recruitment and compliance of HIV-1-infected adults to vaccination...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (1998-11-02)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry